• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 18.60
  • VXN 23.66
  • VXO 18.16
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
VNDA (Vanda Pharmaceuticals Inc.)
Last Trade 30 Dividend/Share 0 PE Ratio 125
Date 12:18:19 PM Dividend Yield 0.000 Return on Assets 5.03
Change 0.71 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -0.34 Price/Sale 10.507
Ask 0 LatestEPS Date 2017-12-31 Price to Book 5.63
Volume 18392 EPS ttm 0.240 Institutional % 153.5
Avg Volume 0.81M Shares Outstanding 52.45M Insider % 4.2
Open 29.49 Float 50.27M Short Ratio null
Prev Close 29.29 Return On Equity 6.64 5 Year Change % 1.204
High 30.41 Consensus EPS -0.03 2 Year Change % 1.178
Low 29.467 No. of Estimate 2.000 1 Year Change % 1.063
52 Week High 33.44 EPS Surprise $ null YTD Change % 0.084
52 Week Low 13.875 EPS Surprise Percent 0 6 Month Change % 0.483
52 Week Change 93.517 EBITDA -1.38M 3 Month Change % 0.373
50 Day MA 24.942 Revenue 44.28M 1 Month Change % 0.116
200 Day MA Gross Profit 39.49M 5 Day Change % 0.031
Market Cap 1536.26M Cash 143.41M 30 Day Change % 0.170
Beta 0.740427 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 1 Short Interest 0
Short Date 0 Revenue Per Employee 162183 Short Ratio null
Data courtesy of IEX
Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of clinical-stage products for various central nervous system disorders. Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is developing Tasimelteon, which is in the orphan designation status for the treatment of non-24 hour sleep/wake disorder in blind individuals without light perception. It is also developing Tasimelteon in Phase II trials for the treatment of depression. The company was incorporated in 2002 and is headquartered in Rockville, Maryland.